Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination...
Under priority review, the FDA has accepted Merck (MRK)and Eisai's(ESALF) applications seeking two new approvals for the combination of Keytruda plus Lenvima, the orally...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks(Biotech Stocks Hitting 52-week Highs May 5)AbbVie Inc. (NYSE: ABBV)Globus...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Sell | Neutral | Strong Buy |
| Technical Indicators | Strong Sell | Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Neutral | Neutral | Neutral | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,351.93 | 2,371.25 | 2,346.16 | +14.58 | +0.62% | 1.44M | NASDAQ | |||
| 319.08 | 322.94 | 318.75 | -0.94 | -0.29% | 15.92M | NASDAQ | |||
| 27.69 | 30.38 | 27.50 | -1.62 | -5.53% | 7.38M | NYSE | |||
| 8.48 | 8.63 | 8.20 | +0.33 | +4.05% | 5.59M | NYSE | |||
| 53.79 | 54.92 | 53.37 | -0.02 | -0.04% | 21.75M | NYSE | |||
| 1.80 | 1.80 | 1.69 | +0.150 | +9.09% | 59.86K | OTC Markets | |||
| 225.31 | 228.79 | 225.05 | -1.11 | -0.49% | 10.55M | NYSE | |||
| 12.24 | 12.30 | 11.82 | +0.54 | +4.62% | 169.88K | NASDAQ | |||
| 287.23 | 287.77 | 283.01 | +1.84 | +0.64% | 888.14K | NYSE | |||
| 6.18 | 6.44 | 6.08 | +0.13 | +2.15% | 3.08M | NYSE | |||
| 244.11 | 245.41 | 237.69 | +3.67 | +1.53% | 333.24K | NYSE | |||
| 151.21 | 157.05 | 148.78 | -2.43 | -1.58% | 7.13M | NASDAQ | |||
| 14.10 | 15.36 | 13.91 | +0.1000 | +0.71% | 16.02M | NASDAQ | |||
| 36.05 | 37.01 | 35.95 | -0.64 | -1.74% | 1.79M | NASDAQ | |||
| 25.38 | 25.52 | 25.32 | +0.08 | +0.32% | 6.34K | NASDAQ |